"PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted 6 months to review the drug. These time frames begin on the date that an NDA is accepted by the FDA as complete."
In other words, that is the time (6 months) that is dictated by the act.
My expection is that it will be quicker, as per the previous annoncement of 9 July 2 Months (Mesoblast expectation and possibly advice given by FDA) - 6 months (maximum required by the act).
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-65
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 50400 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | 1.300 |
6 | 101986 | 1.295 |
6 | 226866 | 1.290 |
4 | 70613 | 1.285 |
5 | 137074 | 1.280 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 50400 | 2 |
1.315 | 2007 | 1 |
1.320 | 40992 | 3 |
1.325 | 20772 | 3 |
1.330 | 139522 | 8 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online